Measurement of piperacillin plasma concentrations in cancer patients with suspected infection

Infection
Tobias RachowMarie von Lilienfeld-Toal

Abstract

Piperacillin (PIP) in combination with tazobactam is commonly used for anti-infective treatment in cancer patients. PIP exerts a time-dependent killing. Thus, the maintenance of plasma concentrations above a pre-defined target concentration for a pre-defined time may be relevant for optimal efficacy. It is assumed that PIP-plasma concentrations above the clinical breakpoint of the target pathogen [Pseudomonas aeruginosa, clinical breakpoint at minimal inhibitory concentration (MIC) 16 mg/L] should be reached for 100% of the dosing interval or >4xMIC (64 mg/L) for 50% of the dosing interval. Whereas studies in the intensive-care setting have shown underdosing in patients with sepsis, little is known about PIP-plasma concentrations in cancer patients. Data of 56 cancer patients who received piperacillin/tazobactam (PIP/TAZ, 4.5 g three times daily) as empiric therapy for suspected infection were analysed at baseline and 4 h after the infusion. Median trough concentrations in steady state [median 3 days (IQR 3-5) after start of PIP/TAZ] were 4.6 mg/L (95% CI 0.3-136.3) and median PIP-plasma concentrations 4 h after infusion were 46.2 mg/L (95% CI 10.1-285.6). A second evaluation 5 days (IQR 4-7) after start of PIP/TAZ confirmed th...Continue Reading

References

Mar 1, 1981·Antimicrobial Agents and Chemotherapy·M I ThompsonE Atkin-Thor
Feb 1, 1982·The Journal of Antimicrobial Chemotherapy·P J De SchepperL Verbist
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
Mar 20, 2004·Nature Reviews. Microbiology·George L Drusano
Dec 29, 2004·International Journal of Antimicrobial Agents·Christine BuckWilhem Dieter Paar
Jul 4, 2006·International Journal of Antimicrobial Agents·Mohammad Reza RafatiMohammad Reza Fazeli
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Feb 24, 2010·Computer Methods and Programs in Biomedicine·Yong ZhangShaofei Xie
Mar 24, 2010·International Journal of Antimicrobial Agents·Andrew A UdyJeffrey Lipman
Jul 3, 2010·Critical Care : the Official Journal of the Critical Care Forum·Fabio Silvio TacconeFrédérique Jacobs
Jan 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of Americaa
Sep 3, 2011·Asia-Pacific Journal of Clinical Oncology·Amitesh Chandra RoyBogda Koczwara
Sep 14, 2011·Archives of Internal Medicine·Livo PaganoUNKNOWN Hema e-Chart Group, Italy
Jun 15, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pranita D TammaSara E Cosgrove
Sep 12, 2012·Current Opinion in Infectious Diseases·Iain J Abbott, Jason A Roberts
Jul 3, 2013·The Cochrane Database of Systematic Reviews·Mical PaulLeonard Leibovici
Apr 2, 2014·Antimicrobial Agents and Chemotherapy·Fekade Bruck SimeJason A Roberts
Apr 8, 2014·Cancer Treatment and Research·Kenneth V I Rolston
May 13, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y HaradaK Yanagihara
May 13, 2014·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Fekade Bruck SimeThomas A Robertson

❮ Previous
Next ❯

Citations

May 8, 2018·Oncology Research and Treatment·Marie von Lilienfeld-Toal, Georg Maschmeyer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.